A detailed history of Royal Bank Of Canada transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, Royal Bank Of Canada holds 8,480 shares of WVE stock, worth $114,564. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,480
Previous 7,782 8.97%
Holding current value
$114,564
Previous $38,000 81.58%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.12 - $9.01 $3,573 - $6,288
698 Added 8.97%
8,480 $69,000
Q2 2024

Aug 14, 2024

BUY
$4.38 - $6.48 $18,680 - $27,637
4,265 Added 121.27%
7,782 $38,000
Q1 2024

Nov 05, 2024

SELL
$3.54 - $6.84 $15,098 - $29,172
-4,265 Reduced 54.81%
3,517 $21,000
Q1 2024

May 15, 2024

SELL
$3.54 - $6.84 $54,211 - $104,747
-15,314 Reduced 81.32%
3,517 $21,000
Q4 2023

Feb 14, 2024

BUY
$4.16 - $6.87 $34,960 - $57,735
8,404 Added 80.6%
18,831 $95,000
Q3 2023

Nov 14, 2023

BUY
$3.56 - $5.75 $5,838 - $9,430
1,640 Added 18.66%
10,427 $59,000
Q2 2023

Aug 14, 2023

BUY
$3.51 - $4.69 $22,225 - $29,697
6,332 Added 257.92%
8,787 $31,000
Q1 2023

May 15, 2023

BUY
$3.58 - $6.3 $1,514 - $2,664
423 Added 20.82%
2,455 $10,000
Q4 2022

Feb 14, 2023

SELL
$3.18 - $7.0 $2,470 - $5,439
-777 Reduced 27.66%
2,032 $14,000
Q3 2022

Nov 14, 2022

BUY
$2.37 - $4.28 $5,256 - $9,493
2,218 Added 375.3%
2,809 $10,000
Q2 2022

Aug 15, 2022

SELL
$1.23 - $3.25 $3,233 - $8,544
-2,629 Reduced 81.65%
591 $2,000
Q1 2022

May 16, 2022

SELL
$2.0 - $3.28 $15,400 - $25,256
-7,700 Reduced 70.51%
3,220 $6,000
Q4 2021

Feb 14, 2022

BUY
$3.14 - $5.15 $22,677 - $37,193
7,222 Added 195.29%
10,920 $34,000
Q3 2021

Nov 15, 2021

BUY
$4.89 - $7.12 $3,080 - $4,485
630 Added 20.53%
3,698 $18,000
Q2 2021

Aug 16, 2021

BUY
$5.65 - $7.47 $17,334 - $22,917
3,068 New
3,068 $20,000

Others Institutions Holding WVE

About Wave Life Sciences Ltd.


  • Ticker WVE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,820,096
  • Market Cap $1.17B
  • Description
  • Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...
More about WVE
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.